Chugai Pharmaceutical Co Ltd 2024 IR

The report highlights Chugai Pharmaceutical's financial and non-financial performance for the fiscal year ended December 31, 2024, marking its 100th anniversary. The company achieved record-high Core revenue exceeding ¥1.17 trillion and Core operating profit of over ¥556 billion. Key achievements include the global launch of its fifth in-house product, PiaSky, and the approval of NEMLUVIO in the United States. Chugai also revised its materiality framework into 16 material issues across three axes: Challenges, Co-creation, and Commitments. Additionally, the company made significant progress toward its Mid-Term Environmental Goals 2030, reducing Scope 1 and 2 emissions by 52.2% compared to 2019.

Company: Chugai Pharmaceutical Co Ltd

Sector: Health Care

Country: Japan

Year: 2024

Type: IR

Pages: 96

Back to company

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co Ltd 2024 Annual Report

Annual Report

The report highlights Chugai Pharmaceutical's financial and non-financial performance for the fiscal year ended December 31, 2024, marking its 100th anniversary. The company achieved record-high Core revenue exceeding ¥1.17 trillion and Core operating profit of over ¥556 billion. Key achievements include the global launch of its fifth in-house product, PiaSky, and the approval of NEMLUVIO in the United States. Chugai also revised its materiality framework into 16 material issues across three axes: Challenges, Co-creation, and Commitments. Additionally, the company made significant progress toward its Mid-Term Environmental Goals 2030, reducing Scope 1 and 2 emissions by 52.2% compared to 2019.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2024

Reporting Period

Jan 1, 2024 - Dec 31, 2024

Fiscal Year

2024

Type

Integrated Report

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Scope 3:

Women in Management

Net Zero Target

Employees